VJHemOnc Podcast
Myeloma 2017 day 1 highlights: immunotherapy advances, a new MM subtype and liquid biopsies
Nov 16, 2017
Doctors Keith Stewart, Leif Bergsagel, and Gareth Morgan discuss the highlights of Myeloma 2017 meeting, including immunotherapy advances, a new MM subtype, and the use of liquid biopsies. They explore advancements in CAR-T cell therapy and combination immunotherapies, the potential for double hit myeloma, and the importance of molecular diagnostics. The podcast also touches on amyloidosis updates and advancements in multiple myeloma diagnosis and imaging.
10:28
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Exciting advances in CAR-T therapy for multiple myeloma show potential in manipulating the immune system to target malignant cells.
- The use of liquid biopsies and genomics in multiple myeloma offers a comprehensive understanding of the disease and the potential for personalized treatment approaches.
Deep dives
Advances in CAR-T Therapy
The podcast discusses the exciting progress in CAR-T therapy for multiple myeloma. Researchers highlight the potential of CAR-T treatment in manipulating the immune system and using bi-specific antibodies to target malignant cells. They express optimism about the clinical effectiveness of CAR-T therapy, which may bring significant benefits to patients. The discussion also touches upon the importance of identifying the right target and delivery system, considering factors like cost and practicality.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
